; and (C) the size of prizes awarded under this section and the effectiveness of such prizes in stimulating innovation. (2) Authorization of appropriations For the purpose of carrying out this subsection, there are authorized to be appropriated, and there are appropriated, $3,000,000 for fiscal year 2020. Such funds shall remain available until expended. . 302. Public funding for clinical trials (a) In general Part E of title IV of the Public Health Service Act ( 42 U.S.C. 287 et seq.) is amended by adding at the end the following: 6 Center for clinical research 485E. Center for clinical research (a) In general There is established within the National Institutes of Health the Center for Clinical Research, for the purpose of conducting clinical trials on drugs, as described in subsection (b), with the intention of obtaining approval of such drug under section 505 of the Federal Food, Drug, and Cosmetic Act or section 351 of this Act. The Director of NIH shall appoint a Director of the Center for Clinical Research referred to in this section as the Director ) not later than 90 days after the date of enactment of the Affordable Medications Act . (b) Clinical trials (1) In general Each year, beginning not later than 1 year after the date of enactment of the Affordable Medications Act , the Director shall select at least 2 molecules, compounds, drugs, or biological products and conduct clinical trials on such molecules, compounds, drugs, or biological products, or enter into contracts with other entities to conduct such clinical trials. (2) Selection of drugs (A) Criteria The Director shall establish criteria, which shall be made public, for acquiring the patent rights for, and selecting, drugs under paragraph (1) to ensure that the drugs selected for clinical trials through the Center— (i) have the potential to address an existing or emerging need, including drugs that can be repurposed to treat a new condition in the case of a national emergency